Amphix Bio

Amphix Bio is a private, preclinical-stage biotech founded in 2021, leveraging a supramolecular chemistry platform to develop regenerative peptide therapeutics. The company has secured significant seed funding and multiple grants, with a pipeline focused on high-unmet-need neurological and musculoskeletal disorders. Key milestones include FDA Orphan Drug and Breakthrough Device designations for its acute spinal cord injury program, positioning it as an emerging player in the regenerative medicine space.

Supramolecular Therapeutic Peptides (STPs): A platform using peptide amphiphiles that self-assemble into nanostructures to provide targeted regenerative signaling and form 3D scaffolds mimicking the extracellular matrix.

Amphix Bio competes in the regenerative medicine space against cell therapy companies (e.g., Mesoblast), gene therapy approaches, and other peptide/biologic platforms. Its fully synthetic, tunable, and scaffold-forming technology aims to differentiate itself by combining potent signaling with structural support, potentially offering advantages in manufacturing and safety over cell-based therapies.